Press Releases from UCB (2 total)
direct/ UCB (BE) - UCB Full-Year 2006 Financial Results
Strong Business Performance and Strategic Move to Become a Next Generation Biopharma Leader
- Revenue growth up 8% to 2.5 billion euro and on like-for-like basis, up 11%
- Growth driven by leading Keppra® performance in the USA and Europe, with net sales up 36% to 761 million euro. Xyzal® sales up 13% and Zyrtec® continued to grow in the U.S.A. up 12%
- Investment in Research & Development up…
direct/ UCB Full-Year 2005 Financial Results
Profit from continuing operations of 270 million euro up 37%,
and on a like-for-like basis up 16%
- Revenue increased by 24% to 2 341 million euro and on a like-for-like basis up 10%
- Growth driven by Keppra® with sales up 34% strengthening market leadership in the U.S.A.
- Allergy sales up 6% with Zyrtec® continuing to grow in the U.S.A. and Japan, and Xyzal® growing strongly in Europe…
